Drug Search Results
More Filters [+]

Tirzepatide

Alternative Names: tirzepatide, ly-3298176, ly3298176, ly 3298176, mounjaro, Zepbound
Latest Update: 2024-02-16
Latest Update Note: News Article

Product Description

Tirzepatide is a novel investigational once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single molecule, representing a new class of medicines being studied for the treatment of type 2 diabetes. (Sourced from: https://investor.lilly.com/news-releases/news-release-details/tirzepatide-results-published-lancet-show-superior-a1c-and-body)

Mechanisms of Action: GLP-1 Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: Fast Track - Obesity|Obesity, Morbid|Overweight *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Japan | Latvia | Lithuania | Poland | Portugal | Romania | Saudi Arabia | Slovakia | Spain | Sweden | Switzerland | United Arab Emirates | United Kingdom | United States

Approved Indications: Type 1 Diabetes | General Diabetes | Type 2 Diabetes

Known Adverse Events: Abdominal Pain | Pain Unspecified | Constipation | Diarrhea | Dyspepsia

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tirzepatide

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czech Republic, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 64

Highest Development Phases

Phase 3: Apnea|Glucose Metabolism Disorders|Heart Failure, Chronic|Heart Failure, Diastolic|Obesity|Overweight|Sleep Apnea, Obstructive|Type 2 Diabetes|Weight Loss

Phase 2: Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Kidney Diseases|Kidney Failure, Chronic|Non-alcoholic Steatohepatitis|Wolfram Syndrome

Phase 1: Healthy Volunteers|Hypoglycemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Tirzepatide

P2

Not yet recruiting

Overweight|Obesity

2028-06-01

jRCT2031220466

P3

Recruiting

Overweight|Obesity

2027-11-30

SURMOUNT-MMO

P3

Active, not recruiting

Obesity|Overweight

2027-10-07

72%

SURPASS-PEDS

P3

Active, not recruiting

Type 2 Diabetes

2027-01-22

Recent News Events